Genomic Aberrations Associated with Erlotinib Resistance in Non-Small Cell Lung Cancer Cells
Total Page:16
File Type:pdf, Size:1020Kb
ANTICANCER RESEARCH 33: 5223-5234 (2013) Genomic Aberrations Associated with Erlotinib Resistance in Non-small Cell Lung Cancer Cells MASAKUNI SERIZAWA1, TOSHIAKI TAKAHASHI2, NOBUYUKI YAMAMOTO2,3 and YASUHIRO KOH1 1Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Shizuoka, Japan; 2Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan; 3Third Department of Internal Medicine, Wakayama Medical University, Kimiidera, Wakayama, Japan Abstract. Background/Aim: Mechanisms of resistance to mutations develop resistance, usually within one year of epidermal growth factor receptor (EGFR)-tyrosine kinase treatment. Therefore, there is an urgent need to elucidate the inhibitors (TKIs) in non-small cell lung cancer (NSCLC) underlying mechanisms of resistance in such tumors to are not fully-understood. In this study we aimed to overcome this obstacle (11-14, 17, 24). Recent studies elucidate remaining unknown mechanisms using erlotinib- suggest that mechanisms of acquired resistance to EGFR- resistant NSCLC cells. Materials and Methods: We TKIs can be categorized into three groups: occurrence of performed array comparative genomic hybridization genetic alterations, activation of downstream pathways via (aCGH) to identify genomic aberrations associated with bypass signaling, and phenotypic transformation (15, 16, 21); EGFR-TKI resistance in erlotinib-resistant PC-9ER cells. therapeutic strategies to overcome these resistance Real-time polymerase chain reaction (PCR) and mechanisms are under development. However, although the immunoblot analyses were performed to confirm the results causes of acquired resistance to EGFR-TKIs have been of aCGH. Results: Among the five regions with copy investigated, in more than 30% of patients with acquired number gain detected in PC-9ER cells, we focused on resistance to EGFR-TKI treatment, the mechanisms remain 22q11.2-q12.1 including v-crk avian sarcoma virus CT10 unknown (15). We previously reported that erlotinib-resistant oncogene homolog-like (CRKL), the overexpression of PC-9ER cells, established from PC-9 NSCLC cells with an which seemed to be associated with EGFR-TKI resistance. EGFR-activating mutation, manifest enhanced cell motility Blockade of downstream phosphatidylinositol 3-kinase which can be abolished by the blockade of transforming (PI3K)/v-akt murine thymoma viral oncogene homolog growth factor-β (TGF-β)/SMAD family member-2 (SMAD2) (AKT) signaling using NVP-BEZ235 suppressed the pathway (18). At the same time, constitutive activation of proliferation of PC-9ER cells, implying the involvement of phosphatidylinositol 3–kinase (PI3K)/v-akt murine thymoma acquired CRKL amplification in EGFR-TKI resistance. viral oncogene homolog (AKT) signaling in PC-9ER cells Conclusion: Acquired CRKL amplification was identified as was observed and this might confer resistance to EGFR- contributing to EGFR-TKI resistance; this cell line model TKIs. However, the mechanism responsible for this activated can be utilized to study this resistance mechanism. signaling on the genetic level remains unclear. Array comparative genomic hybridization (aCGH) Despite a dramatic initial response to the epidermal growth analysis is a high-resolution, genome-wide screening factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) technology that allows for rapid survey of genomic gefitinib and erlotinib, the majority of patients with non- instability, especially of copy number alterations, which are small cell lung cancer (NSCLC) with EGFR-activating key genetic aberrations relevant to the development and progression of human cancers (20). Moreover, aCGH analysis is useful as a means to explore mechanisms of resistance to EGFR-TKIs. For example, met proto-oncogene Correspondence to: Yasuhiro Koh, MD, Drug Discovery and (MET) amplification, a major cause of resistance to EGFR- Development Division, Shizuoka Cancer Center Research Institute, TKIs was detected in gefitinib-resistant NSCLC by aCGH 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411- analysis (4). 8777, Japan. Tel: +81 559895222, Fax: +81 559896085, e-mail: [email protected] In the present study, we aimed to clarify genomic aberrations, especially copy number alterations, relevant to Key Words: EGFR-TKI resistance, erlotinib, amplification, copy- EGFR-TKI resistance mechanisms in PC-9ER cells using number alteration, CRKL, non-small cell lung cancer. aCGH analysis. 0250-7005/2013 $2.00+.40 5223 ANTICANCER RESEARCH 33: 5223-5234 (2013) Table I. Chromosome aberrations in PC-9ER1 cells. Chr Cytoband Start End Overlap Number of Log2 Log2 Number of Genes (hg19) (hg19) detected in aCGH probes ratio ratio genes included in PC-9ER1 included (amplifi- (deletion) included in chromosome and in genomic cation) chromosome aberration PC-9ER4 aberration aberration 1 p35.2- 31,964,879 32,473,479 l 204 –1.07 8 LOC284551, TINAGL1, HCRTR1, PEF1, p35.1 COL16A1, BAI2, SPOCD1, PTP4A2 1 p31.1 72,341,387 72,544,038 104 –1.10 1 NEGR1 2 q14.2- 120,609,630 122,530,342 l 724 1.09 12 PTPN4, EPB41L5, TMEM185B, RALB, q14.3 INHBB, LOC84931, GLI2, TFCP2L1, CLASP1, RNU4ATAC, MKI67IP, TSN 2 q22.2 142,338,612 142,570,218 115 –1.47 1 LRP1B 3 p14.2 60,070,343 60,113,818 l 23 –2.73 1 FHIT 3 p14.2 60,196,167 60,329,532 l 63 –2.83 1 FHIT 3 p14.2 60,344,382 60,375,603 l 18 –3.33 1 FHIT 3 p14.2 60,536,419 60,603,993 l 33 2.46 1 FHIT 3 p14.2 62,479,806 62,541,800 l 33 –1.55 1 CADPS 3 p13 71,345,692 71,395,229 l 27 –1.50 1 FOXP1 8 q24.12- 119,739,051 130,277,369 l 3,329 1.56 45 TNFRSF11B, COLEC10, MAL2, NOV, q24.21 ENPP2, TAF2, DSCC1, DEPDC6, COL14A1, MRPL13, MTBP, SNTB1, HAS2, HAS2AS, ZHX2, DERL1, WDR67, FAM83A, LOC100131726, C8orf76, ZHX1, ATAD2, WDYHV1, FBXO32, KLHL38, ANXA13, FAM91A1, FER1L6, TMEM65, TRMT12, RNF139, TATDN1, NDUFB9, MTSS1, LOC157381, ZNF572, SQLE, KIAA0196, NSMCE2, TRIB1, FAM84B, POU5F1B, LOC727677, MYC, PVT1 8 q24.23 136,467,502 136,771,745 l 120 1.24 1 KHDRBS3 10 p13-p11.1 16,013,438 38,629,589 l 7,704 –1.01 90 PTER, C1QL3, RSU1, CUBN, TRDMT1, VIM, ST8SIA6, PTPLA, STAM, FAM23A, MRC1, MRC1L1, SLC39A12, CACNB2, NSUN6, ARL5B, PLXDC2, NEBL, C10orf113, C10orf114, C10orf140, MLLT10, DNAJC1, COMMD3, BMI1, SPAG6, PIP4K2A, ARMC3, MSRB2, PTF1A, C10orf67, OTUD1, KIAA1217, PRINS, ARHGAP21, PRTFDC1, ENKUR, THNSL1, LOC100128811, GPR158, MYO3A, GAD2, APBB1IP, C10orf50, LOC731789, PDSS1, ABI1, NCRNA00202, ANKRD26, YME1L1, MASTL, ACBD5, LOC387646, PTCHD3, RAB18, MKX, ARMC4, MPP7, WAC, BAMBI, LYZL1, LOC387647, SVIL, KIAA1462, MTPAP, LOC729668, MAP3K8, LYZL2, ZNF438, LOC220930, ZEB1, ARHGAP12, KIF5B, EPC1, CCDC7, C10orf68, ITGB1, NRP1, PARD3, CUL2, CREM, CCNY, GJD4, FZD8, ANKRD30A, ZNF248, ZNF25, ZNF33A, ZNF37A, LOC100129055 13 q31.3 94,063,273 94,377,155 l 163 –2.82 1 GPC6 15 q22.2 60,661,598 60,713,059 l 32 –1.43 2 ANXA2, NARG2 19 q13.11 34,965,663 34,992,122 16 –1.01 1 WTIP 22 q11.21- 20,889,601 29,555,904 l 4,243 1.16 108 MED15, POM121L4P, TMEM191A, q12.1 PI4KA, SERPIND1, SNAP29, CRKL, AIFM3, LZTR1, THAP7, FLJ39582, MGC16703, P2RX6, SLC7A4, P2RX6P, Table I. Continued 5224 Serizawa et al: Genomic Aberrations Associated with EGFR-TKI Resistance in NSCLC Table I. Continued Chr Cytoband Start End Overlap Number of Log2 Log2 Number of Genes (hg19) (hg19) detected in aCGH probes ratio ratio genes included in PC-9ER1 included (amplifi- (deletion) included in chromosome and in genomic cation) chromosome aberration PC-9ER4 aberration aberration LOC400891, POM121L8P, RIMBP3C, RIMBP3B, HIC2, PI4KAP2, UBE2L3, YDJC, CCDC116, SDF2L1, PPIL2, YPEL1, MAPK1, PPM1F, TOP3B, VPREB1, LOC96610, ZNF280B, ZNF280A, PRAME, LOC648691, POM121L1P, GGTLC2, RTDR1, GNAZ, RAB36, BCR, ZDHHC8P, IGLL1, C22orf43, LOC91316, RGL4, ZNF70, VPREB3, C22orf15, CHCHD10, MMP11, SMARCB1, DERL3, SLC2A11, MIF, GSTT2, DDTL, DDT, GSTTP1, LOC391322, GSTT1, GSTTP2, CABIN1, SUSD2, GGT5, POM121L9P, CYTSA, ADORA2A, C22orf45, UPB1, C22orf13, SNRPD3, GGT1, C22orf36, LOC644165, POM121L10P, PIWIL3, TOP1P2, SGSM1, TMEM211, KIAA1671, CRYBB3, CRYBB2, IGLL3, LRP5L, ADRBK2, MYO18B, SEZ6L, ASPHD2, HPS4, SRRD, TFIP11, TPST2, CRYBB1, CRYBA4, MIAT, MN1, PITPNB, LOC284900, TTC28, CHEK2, HSCB, CCDC117, XBP1, ZNRF3, C22orf31, KREMEN1 22 q12.1- 29,560,131 30,165,998 l 312 –1.28 17 KREMEN1, EMID1, RHBDD3, q12.2 EWSR1, GAS2L1, RASL10A, AP1B1, SNORD125, RFPL1S, RFPL1, NEFH, THOC5, NIPSNAP1, NF2, CABP7, ZMAT5, UCRC Materials and Methods aCGH experiments and data analysis. aCGH analysis was performed with 500 ng genomic DNA from PC-9 cells (reference), and PC-9ER1 Cell culture and reagents. The human lung adenocarcinoma cell or PC-9ER4 cells (experimental sample) using SurePrint G3 Human line PC-9 harboring an EGFR-activating mutation (E746-A750del CGH 1×1M Oligo Microarrays (Agilent Technologies, Palo Alto, CA, at exon 19) was provided by Dr. Fumiaki Koizumi (National USA) according to standard procedures. Genomic Workbench Cancer Center Hospital, Tokyo, Japan). Erlotinib-resistant PC-9ER software ver. 7.0.4.0 (Agilent Technologies) was used to identify cells (PC-9ER1 and PC-9ER4) were established from PC-9 cells consecutive genomic aberrations using the statistical algorithm ADM- as previously reported (18). All the cell lines used in this study 2 with a sensitivity threshold of 10.0, and genomic aberration filters were maintained in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) (absolute average of log2 ratios of 1.0 in more than10 consecutive supplemented with 10% heat-inactivated fetal bovine serum (FBS; probes). Gene annotation enrichment analysis of genes involved in regions of genomic aberration was performed with The Database for Invitrogen) in humidified air containing 5% CO2 at 37˚C. Erlotinib and NVP-BEZ235 were purchased from LC laboratories (Woburn, Annotation, Visualization and Integrated Discovery (DAVID) MA, USA). Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov/) (6, 7). The acceptable statistical significance level of the gene annotation Nucleic acid sample preparation. Genomic DNA of PC-9 and PC- enrichment analysis was set at a p-value of lower than 0.1. 9ER cells was extracted using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.